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1486Objective: The purpose of the present study was to evaluate the effect of atorvastatin on oxidative stress and
angiogenesis in ischemic myocardium in a clinically relevant porcine model of the metabolic syndrome.
Methods: Sixteen Ossabaw pigs were fed either a high-fat diet alone or a high-fat diet supplemented with ator-
vastatin (1.5 mg/kg daily) for 14 weeks. Chronic myocardial ischemiawas induced by ameroid constrictor place-
ment around the circumflex artery. After 6 months of the diet, myocardial perfusion was measured at rest and
with demand pacing. The heart was harvested for analysis of perfusion, microvessel relaxation, protein expres-
sion, and oxidative stress.
Results: Both groups had similar endothelium-dependent microvessel relaxation to adenosine diphosphate and
endothelium-independent relaxation to sodium nitroprusside.Myocardial perfusion in the ischemic territory was
also not significantly different either at rest or with demand pacing. Atorvastatin treatment increased total myo-
cardial protein oxidation and serum lipid peroxidation. However, the expression of markers of oxidative stress,
including NOX2, RAC1, myeloperoxidase, and superoxide dismutase 1, 2, and 3, were not statistically different.
The expression of proangiogenic proteins endothelial nitric oxide synthase, phosphorylated endothelial nitric
oxide synthase (Ser 1177), phosphorylated adenosine monophosphate kinase (Thr 172), phosphorylated extra-
cellular signal-regulated kinase (T202, Y204), and vascular endothelial growth factor were all upregulated in the
atorvastatin group.
Conclusions:Atorvastatin increased the capillary and arteriolar density and upregulated the proangiogenic pro-
teins endothelial nitric oxide synthase and phosphorylated endothelial nitric oxide synthase, phosphorylated
adenosine monophosphate kinase, phosphorylated extracellular signal-regulated kinase, and vascular endothe-
lial growth factor in a swine model of the metabolic syndrome. However, it failed to increase myocardial per-
fusion. Atorvastatin treatment was associated with increased myocardial and serum oxidative stress, which
might contribute to the lack of collateral-dependent perfusion in the setting of angiogenesis. (J Thorac Cardio-
vasc Surg 2012;144:1486-93)3-Hydroxy-3-methylglutaryl–co-enzyme A reductase in-
hibitors, or statins, are a widely prescribed medication for
the treatment and prevention of coronary artery disease.
In addition to its lipid-lowering effects, statins also protect
against ischemia–reperfusion injury, reduce vascular in-
flammation, and improve endothelial function.1-3 Another
important pleiotropic effect is statin’s dose-dependent bi-
phasic effect on angiogenesis.4,5 At low doses, statinse Division of Cardiothoracic Surgery, Cardiovascular Research Center,
n University Warren Alpert School of Medicine, Providence, RI.
for this research was provided by the National Heart, Lung, and Blood Insti-
grants R01HL46716, R01HL69024, and R01HL85647, Dr Sellke), National
tes of Health Training grant 5T32-HL076134 (Dr Lassaletta), and National
tes of Health Training grant 5T32-HL094300-03 (Drs Chu and Elmadhun).
res: Authors have nothing to disclose with regard to commercial support.
the 38th Annual Meeting of The Western Thoracic Surgical Association,
, Hawaii, June 27-30, 2012.
d for publication June 25, 2012; revisions received Aug 2, 2012; accepted for
ation Aug 23, 2012; available ahead of print Sep 19, 2012.
for reprints: Frank W. Sellke, MD, Division of Cardiothoracic Surgery, Car-
scular Research Center, Warren Alpert Medical School of Brown University,
ley St, MOC 360, Providence, RI 02905 (E-mail: fsellke@lifespan.org).
23/$36.00
ht  2012 by The American Association for Thoracic Surgery
.doi.org/10.1016/j.jtcvs.2012.08.065
The Journal of Thoracic and Cardiovascular Surinduce angiogenesis by promoting endothelial cell
migration, maturation, and survival. At high statin doses,
the proangiogenic effect is reversed, and statins become
anti-angiogenic by inducing endothelial cell apoptosis. In
a previous study conducted in our laboratory, high-dose
atorvastatin (3 mg/kg) administration in hypercholesterol-
emic swine resulted in improved endothelial function with-
out improving the angiogenic response in the chronically
ischemic myocardium.6,7 Given atorvastatin’s known
dose-dependent effect on angiogenesis, we hypothesized
that low-dose atorvastatin (1.5 mg/kg) would result in im-
proved angiogenesis in chronically ischemic myocardium
in a large animal model of the metabolic syndrome.METHODS
Animal Model
Sixteen intact male Ossabaw miniswine (Purdue Ossabaw Facility, In-
diana University, Indianapolis, Ind) were fed 500 g/day of high-
cholesterol chow consisting of 4% cholesterol, 17.2% coconut oil, 2.3%
corn oil, 1.5% sodium cholate, and 75% regular chow (Sinclair Research,
Columbia, Mo). After 14 weeks of diet initiation, all pigs underwent surgi-
cal placement of an ameroid constrictor to induce chronic myocardialgery c December 2012
Abbreviations and Acronyms
AMPK ¼ adenosine monophosphate kinase
DNP ¼ 2,4-dinitrophenyl
eNOS ¼ endothelial nitric oxide synthase
ERK ¼ extracellular signal-regulated kinase
OHC ¼ oral hypercaloric/hypercholesterolemic
diet
OHCS ¼ oral hypercaloric/hypercholesterolemic
diet plus 1.5 mg/kg atorvastatin daily
pERK ¼ phosphorylated ERK
SOD ¼ superoxide dismutase
SNP ¼ sodium nitroprusside
TIMI ¼ Thrombolysis in Myocardial Infarction
VEGF ¼ vascular endothelial growth factor
VEGFR2 ¼ VEGF receptor 2
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Sischemia (see ‘‘Surgical Interventions’’). Postoperatively, the 8 pigs contin-
ued to consume an oral hypercaloric/hypercholesterolemic diet (OHC)
alone, and the diet of the other 8 pigs was supplemented with oral 1.5
mg/kg atorvastatin daily (OHCS). At 11 weeks after ameroid constrictor
placement, all the pigs were weighed and underwent functional cardiac
and hemodynamic measurements, were put to death, and the cardiac tissue
was harvested. All the pigs were observed to ensure complete consumption
of food and supplement, had unlimited access to water, and were housed in
a warm, nonstressful environment for the duration of the experiment.
Surgical Interventions
Anesthesia. Anesthesiawas inducedwith an intramuscular injection of
telazol (4.4 mg/kg). The pigs were endotracheally intubated and mechan-
ically ventilated at 12 to 20 breaths/min. General anesthesia was main-
tained with a gas mixture of oxygen at 1.5 to 2 L/min and isoflurane at
0.75% to 3.0% concentration.
Ameroid constrictor placement. The pigs were given a single
dose of intravenous enrofloxacin, 5 mg/kg, for antibiotic prophylaxis,
and general anesthesia was induced and maintained. The pigs were pre-
pared and draped in the usual sterile fashion. The heart was exposed
through a left minithoracotomy and pericardiotomy. The left atrial append-
agewas retracted, and the proximal left circumflex artery was dissected im-
mediately distal to the left main coronary artery. The circumflex artery was
occluded for 2 minutes, during which, 5 mL of isotope-labeled gold micro-
spheres (BioPhysics Assay Laboratory, Worcester, Mass) was injected into
the left atrium to establish shadow labeling of the ischemic myocardium.
The ameroid constrictor was placed around the proximal left circumflex
artery, just after its branching from the left main coronary artery (Research
Instruments SW, Escondito, Calif). The pericardium was loosely reap-
proximated, followed by a layered closure of the surgical incision.
Postoperative pain was controlled with a single dose of intramuscular
buprenorphine (0.03 mg/kg) and a 72-hour fentanyl patch (4 mg/kg). All
the pigs received 325 mg of aspirin daily starting 1 day preoperatively
and continuing for 5 days for prophylaxis against thromboembolic events.
All the pigs continued the perioperative antibiotic (oral enrofloxacin
68 mg/day for 5 days).
Cardiac harvest. Blood samples were drawn from the jugular
vein before death and tissue harvest. Blood glucose measurements were
taken at baseline (fasting) and 30 and 60 minutes after an intravenous
0.5-mg/kg dextrose infusion. Under general anesthesia, a 5F arterial sheath
was placed in the right femoral artery by cutdown, and coronary
angiography was performed with an Amplatz R1 catheter (Cordis Corp,The Journal of Thoracic and CarBridgewater, NJ) and advanced to the right and left coronary artery ostia.
Contrast was injected into each side to visualize the coronary vessels.
The angiograms were read by a cardiologist unaware of the experimental
groups and scored according to the Thrombolysis in Myocardial Infarction
myocardial perfusion grade (score 0-3). The heart was then exposed byway
of a median sternotomy. After microsphere injection (see ‘‘Myocardial Per-
fusion’’), the pigs were killed by exsanguination, and chronically ischemic
myocardial samples from the left circumflex territory were collected for ad-
ditional analysis. The cardiac tissue was rapidly frozen in liquid nitrogen
for protein expression and histologic analysis and placed in 4C Krebs so-
lution for microvessel studies or desiccated at 60C for perfusion analysis.
The Institutional Animal Care and Use Committee of the Rhode Island
Hospital approved all experiments. The pigs were cared for in compliance
with the ‘‘Principles of Laboratory Animal Care’’ formulated by the
National Society for Medical Research and the ‘‘Guide for the Care and
Use of Laboratory Animals’’ (National Institutes of Health publication
no. 5377-3, 1996).
Myocardial Perfusion
Myocardial perfusion was measured by injecting gold isotope-labeled
microspheres (Biophysics Assay Laboratory) into the left atrium at ame-
roid placement during a brief left circumflex artery occlusion. At the final
operation, Lutetium microspheres were injected into the left atrium at rest,
and Europium microspheres were injected during pacing at 160 beats/min.
During microsphere injection, the blood was simultaneously withdrawn
from a femoral artery catheter. Samples of the ischemic myocardium in
the circumflex artery distribution and blood were dried at 60C for more
than 48 hours, and the microsphere density was quantified using a gamma
counter after exposure to neutron bean radiation (Biophysics Assay Labo-
ratory). The myocardial blood flow to each samplewas calculated using the
following equation:
Blood Flow ¼Withdrawal Rate
Tissue Weight
3
Tissue Microsphere Count
Blood Microsphere Count
Microvessel Studies
Epicardial arterioles ranging in size from 80 to 120 mm in diameter and
1 to 2 mm in length from the chronically ischemic left circumflex territory
were isolated, cannulated, and pressurized (40 mm Hg) with dual micropi-
pettes in a microvessel chamber, as previously described.8 The vessels were
preconstricted by 20% to 50% of their baseline diameter with the throm-
boxane-A2 analog U46619 (0.1-1.0 mM). The microvessels were exposed
to an endothelium-dependent vasodilator adenosine-50-diphosphate (109
to 104 mol/L), which is a receptor-mediated vasodilator that acts mainly
through nitric oxide. The microvessels were also treated with an
endothelium-independent vasodilator superoxide dismutase (SOD) (109
to 104 mol/L), a cyclic guanosine monophosphate-mediated vasodilator
(Sigma-Aldrich, St Louis, Mo), as previously described.8 The percentage
of relaxation from the initial preconstricted diameter was recorded.
Immunohistochemical Staining for Angiogenesis
The frozen myocardium was cut into 12-mm-thick sections and fixed in
10% formalin for 10 minutes. The sections were blocked with 1% bovine
serum albumin in phosphate-buffered saline for 1 hour at room temperature
and incubated with antibodies against the porcine endothelial marker
CD-31 (R&D Systems, Minneapolis, Minn) and smooth muscle actin
(Sigma-Aldrich), followed by the appropriate Alexa-Fluor conjugated an-
tibody (Jackson ImmunoResearch, West Grove, Pa) for 45 minutes. The
slides were then mounted with Vectashield with 40,6-diamidino-
2-phenylindole (Vector Laboratories, Burlingame, Calif). Images were
captured at 203 magnification with a Nikon E800 Eclipse microscope
(Nikon, Tokyo, Japan) at the same exposure in 3 random fields. Capillariesdiovascular Surgery c Volume 144, Number 6 1487
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rioles were defined by colocalization of smooth muscle actin and CD31
staining. Arteriolar density and capillary density were measured using Im-
age J software (National Institutes of Health, Bethesda, Md) in a blinded
fashion. The percentage of capillary and arteriolar density for each pig
was averaged from the 3 randomly selected myocardial tissue sections.
Oxidative Stress Assays
Oxidized proteins from chronically ischemic myocardium were
detected using a commercial kit (Oxyblot, Millipore, Bellerica, Mass).
The carbonyl groups in oxidized protein side chains are derivatized
to 2,4-dinitrophenyl (DNP)-hydrazone by incubating lysates with
2,4-dinitrophenylhydrazine. The DNP-derivatized proteins were separated
on a polyacrylamide gel electrophoresis and transferred to a polyvinyldine
diflouride membrane. The membranes were probed with primary antibody
to the DNP moiety of the proteins, followed by incubation with a horserad-
ish peroxidase-linked secondary antibody. Immune complexes were visual-
ized with enhanced chemiluminescense, and the images were capturedwith
a digital camera system (G-Box, Syngene, Cambridge, United Kingdom).
Band densitometry was quantified as arbitrary light units using Image-J
software (National Institutes of Health).
A commercial enzyme-linked immunosorbent assay kit was used to de-
tect the serum 8-isoprostane levels as a marker of serum lipid peroxidation
(Cayman Chemical, Ann Arbor, Mich). 8-Isoprostane is an eicosanoid pro-
duced by the oxidation of phospholipids by oxygen free radicals. Serum
samples, 8-isoprostane-acetylcholinesterase conjugate, and 8-isoprostane
antiserum were added to a microplate coated with mouse monoclonal an-
tibody. Acetylcholinesterase substratewas added, resulting in an enzymatic
reaction that produced a distinct yellow that can be detected spectrophoto-
metrically at 412 nm. The signal intensity was inversely proportional to the
serum 8-isoprostane levels. 8-Isoprostane levels were quantified using the
standards provided by the manufacturer.
Protein Expression
Forty micrograms of the radioimmunoprecipitation assay (Boston Bio-
Products, Ashland, Mass) soluble fraction of myocardial lysates were frac-
tionated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis 3%
to 8% tris-acetate gel (NuPage Novex Mini Gel; Invitrogen, Carlsbad, Ca-
lif) for molecular weight targets greater than 100 kD and 4% to 12% Bis-
Tris gels for molecular weight targets less than 100 kD (NuPage Novex
Mini Gel, Invitrogen). The protein was then transferred to polyvinylidene
difluoride membranes (Millipore, Bedford, Mass) and incubated overnight
at 4C with primary antibodies at the dilutions recommended by the man-
ufacturer against phosphorylated Akt (Ser 473), Akt, phosphorylated endo-
thelial nitric oxide synthase (peNOS; Ser 1177), eNOS, RAC1, vascular
endothelial growth factor (VEGF) receptor 2 (VEGFR2), extracellular
signal-regulated kinase (ERK), phosphorylated ERK (pERK; T202,
Y204; all from Cell Signaling, Danvers, Mass), SOD3 and myeloperoxi-
dase (both from Abcam, Cambridge, Mass), angiostatin and VEGF (both
from Millipore, Billerica, Mass), SOD1 and SOD2 (both from Stressgen
Farmingdale, NY), and NOX2 (Sigma-Aldrich). The membranes were in-
cubated with the appropriate horseradish peroxidase-linked secondary an-
tibody for 1 hour at room temperature (Jackson ImmunoResearch). The
immune complexes were visualized with enhanced chemiluminescense,
and the images were captured with a digital camera system. Band densi-
tometry was quantified as arbitrary light units using Image-J software
(National Institutes of Health). All membranes were probed with glyceral-
dehyde-3-phosphate dehydrogenase (Cell Signaling) to correct for loading
error.
Histologic Examination
Trichrome and picosirius red staining was performed on frozen tissue
sections by the Pathology and Histology Core Facility at Rhode Island1488 The Journal of Thoracic and Cardiovascular SurHospital. Images were obtained using Aperio ScanScope technology
(Aperio, Vista, Calif) and captured at 53 magnification.
Statistical Analysis
All results are reported as mean standard error of the mean.Microves-
sel responses and postdextrose challenge serum glucose levels were ana-
lyzed with 2-way analysis of variance followed by a post-hoc Bonferroni
test. Student t test was used to compare the mean values of all other studies
using GraphPad Prism, version 5.0 Software (GraphPad Software Inc, San
Diego, Calif).RESULTS
Animal Model
All the pigs included in the analysis survived the entire
experiment. One pig in the OHC group and 2 in the
OHCS group died 2, 6, and 1 day postoperatively, respec-
tively. Necropsy did not reveal a clear myocardial infarction
or other cause of death, and it was assumed they died after
acute arrhythmia leading to sudden cardiac death. The pigs
that did not survive to completion of the experiment were
excluded from the analysis and replaced with new pigs.
In a previously published study, we reported that the
OHC group developed the hallmarks of the metabolic syn-
drome, including obesity, insulin resistance, glucose intol-
erance, dyslipidemia, and hypertension, compared with
the Ossabaw swine fed normal chow.9 In the present study,
the body mass index and blood glucose level in response to
the dextrose challenge was similar in the OHC and OHCS
groups (Table 1). Also, the Thrombolysis in Myocardial In-
farction perfusion grade in the collateral dependent zone
was not statistically different between the 2 groups.Myocardial Perfusion
Myocardial perfusion to the chronically ischemic cir-
cumflex artery territory was measured at the final operation,
and no difference in flow was found at rest between the
OHC and OHCS groups (0.61  0.08 mL/min/g and 0.56
 0.07 mL/min/g, respectively; P ¼ .62). Also, no differ-
ence was seen in myocardial perfusion during demand pac-
ing at 160 beats/min in the OHC and OHCS groups (0.55
0.03 mL/min/g and 0.38  0.10 mL/min/g, respectively;
P ¼ .13; Figure 1).Microvessel Relaxation
Microvessel relaxation in response to adenosine-50-di-
phosphate, an endothelium-dependent vasodilator, and so-
dium nitroprusside (SNP), an endothelium-independent
vasodilator, was not significantly different in the OHCS
group compared with the OHC group (2-way analysis of
variance, P ¼ .22 and P ¼ .81, respectively; Figure 1).
The baseline diameter and percentage of preconstriction
was also not significantly different in the adenosine-50-di-
phosphate and SNP-treated microvessels in each group
(Figure 1).gery c December 2012
TABLE 1. Thrombolysis in Myocardial Infarction scores, body mass
index, and dextrose challenge results
Variable OHC OHCS P value
TIMI 1.71  0.36 1.50  0.34 .68
BMI (mg/kg2) 34.87  0.74 37.31  1.14 .09
Dextrose challenge (min)
0 59.63  9.56 54.13  4.41 .20*
30 214.10  21.06 206.00  13.75
60 130.00  21.90 93.00  14.79
No difference seen in TIMI, BMI, or response to dextrose challenge in OHC and
OHCS groups. OHC, Oral hypercaloric/hypercholesterolemic diet; OHCS, oral hy-
percaloric/hypercholesterolemic diet plus 1.5 mg/kg atorvastatin daily; TIMI, Throm-
bolysis in Myocardial Infarction; BMI, body mass index. *Analysis of variance.
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The percentage of capillary density/high power field in
the OHCS group was significantly greater than in the
OHC group (13.9  1.2% vs 9.5  0.4%, P ¼ .02). The
percentage of arteriolar density/high power field was alsoFIGURE 1. Myocardial perfusion and coronary microvessel reactivity. A, Myo
myocardial perfusion at rest or during demand pacing at 160 beats/min. B, M
endothelium-dependent (adenosine diphosphate [ADP]) or endothelium-indepen
cholesterolemic diet (OHC) and oral hypercaloric/hypercholesterolemic diet p
diameter and percentage of preconstriction. No difference was seen in base
microvessels.
The Journal of Thoracic and Carsignificantly increased in the OHCS group compared with
the OHC group (7.71  0.8% vs 3.2  0.9%, P ¼ .003;
Figure 2). Significant upregulation was seen of the proan-
giogenic proteins eNOS (fold change compared with
that for OHC, 1.67  0.14; P ¼ .001), peNOS (1.26 
0.06, P ¼ .01), phosphorylated adenosine monophosphate
kinase (AMPK) (1.62  0.14, P ¼ .03), pERK (3.03 
0.47, P ¼ .002), and VEGF (1.29  0.08, P ¼ .04) in the
OHCS group and a significant decrease in Akt (0.72 
0.07, P ¼ .01) and phosphorylated Akt (0.56  0.08,
P ¼ .02). Also, a trend was seen toward decreased anti-
angiogenesis protein angiostatin in the OHCS group,
but this did not reach statistical significance (0.58  0.08,
P ¼ .13; Figure 2).Oxidative Stress
Total myocardial protein oxidation as measured by the
Oxyblot assay (Millipore) was significantly increased incardial perfusion at rest and with demand pacing. No difference was seen in
icrovessel reactivity. No difference was seen in microvessel reactivity to
dent (sodium nitroprusside [SNP]) vasodilators in oral hypercaloric/hyper-
lus 1.5 mg/kg atorvastatin daily (OHCS) groups. C, Baseline microvessel
line diameter or percentage of preconstriction in ADP- or SNP-treated
diovascular Surgery c Volume 144, Number 6 1489
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FIGURE 2. Atorvastatin and angiogenesis. A, Endothelial cell density staining for CD31. Significant increase seen in capillary density in oral hypercaloric/
hypercholesterolemic diet plus 1.5 mg/kg atorvastatin daily (OHCS) compared with oral hypercaloric/hypercholesterolemic diet (OHC) groups. B, Arteri-
olar density staining for smooth muscle actin. No significant increase was seen in arteriolar density in OHCS group compared with OHC. C, Western blot
analysis of angiogenesis protein expression showing a significant increase in proangiogenic proteins endothelial nitric oxide synthase (eNOS), phosphor-
ylated eNOS (peNOS), phosphorylated adenosine monophosphate kinase (pAMPK), phosphorylated extracellular signal-regulated kinase (pERK), and
vascular endothelial growth factor (VEGF) and a significant decrease in Akt and phosphorylated Akt (pAkt). Also, a trend was seen toward decreased
anti-angiogenesis protein angiostatin. *P<.05 and **P<.01. AMPK, Adenosine monophosphate kinase; HPF, high power field; VEGFR2, VEGF receptor 2.
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OHC, 1.39  0.11; P ¼ .04). Also, significantly increased
lipid peroxidation, as measured by the 8-isoprostane1490 The Journal of Thoracic and Cardiovascular Surlevels, was seen in the OHCS group (571.4  72.8
pg/mL) compared with OHC (373.0  29.9 pg/mL,
P ¼ .04). Although a significant increase was seen ingery c December 2012
Elmadhun et al Evolving Technology/Basic Scienceprotein and lipid oxidation, no difference was found in the
expression of the proteins involved in oxidative stress, in-
cluding myeloperoxidase, NOX2, SOD1, SOD2, SOD3, or
RAC1 (Figure 3).
Myocardial Collagen and Fibrosis
The chronically ischemic myocardium was stained for
collagen (picosirius red stain) and fibrosis (trichrome stain),
and no difference was seen in the collagen area fraction or
fraction of intramyocardial fibrosis (P ¼ .26 and P ¼ .24,
respectively; Figure 4).
DISCUSSION
The results of the present study have demonstrated that
high-fat-fed Ossabaw swine with the metabolic syndrome
treated with low-dose atorvastatin (1.5 mg/kg) for 14 weeks
had an improved angiogenic response in terms of vascular
density and increased oxidative stress. However, this failed
to lead to increased myocardial perfusion in the collateral-
dependent myocardium.
Angiogenesis is a complex process that involves a fine
balance between proangiogenesis and anti-angiogenesis
mediators. This balance is easily disturbed by coexisting
illnesses such as diabetes or hypercholesterolemia or med-
ication. Angiogenesis is activated under conditions such as
tissue ischemia and inflammation and is mediated by pro-
liferation, migration, and differentiation of endothelial
cells and endothelial progenitor cells.10 In some studies,
statins have been shown to activate angiogenesis byFIGURE 3. Oxidative stress profile. A, Myocardial protein oxidation showing
terolemic diet plus 1.5 mg/kg atorvastatin daily (OHCS) compared with oral hy
idation. Significantly increased lipid peroxidation was seen in OHCS group com
expression showing no difference in expression of proteins involved in oxidativ
thelial nitric oxide synthase; pAkt, phosphorylated Akt; pAMPK, phosphorylated
factor; VEGFR2, VEGF receptor 2.
The Journal of Thoracic and Carpromoting migration and proliferation of endothelial pro-
genitor cells derived from bone marrow and tissue in the
foci of ischemia and neovascularization.11 Although not
entirely well understood, Akt signaling is central in
statin-mediated angiogenesis by promoting endothelial
cell survival by inhibiting apoptosis, activating eNOS,
and increasing nitric oxide bioavailability.12 However, in
the present study, Akt and phosphorylated Akt was down-
regulated. In contrast, significant upregulation of phos-
phorylated AMPK and pERK was seen in the OHCS
group, consistent with previous studies of statin treat-
ment.13 AMPK has been shown to activate and phosphor-
ylate eNOS, and ERK has been shown to promote
cell survival.13,14 Thus, atorvastatin seems to promote
angiogenesis in an Akt-independent manner, perhaps
through AMPK and ERK upregulation.
The observed histologic increase in capillary and
arteriolar density in the ischemic myocardium was sup-
ported by the protein expression analysis, in which ator-
vastatin increased expression of the proangiogenic
proteins eNOS, peNOS, and VEGF. Previous studies
have shown that statin treatment stabilizes eNOS
mRNA, resulting in increased eNOS protein, which
might account for the increased eNOS protein expression
in the ischemic myocardium.5,15 Increased nitric oxide
bioavailability promotes angiogenesis by increasing
VEGF expression.16-18 VEGF binds VEGFR2, which
promotes cell survival and proliferation by activating
ERK and inhibiting apoptosis.19 The decreased VEGFR2significantly increased protein oxidation in oral hypercaloric/hypercholes-
percaloric/hypercholesterolemic diet (OHC) groups. B, Serum lipid perox-
pared with OHC group. C, Western blot analysis of oxidative stress protein
e stress. *P<.05. AMPK, Adenosine monophosphate kinase; eNOS, endo-
AMPK; peNOS, phosphorylated eNOS;VEGF, vascular endothelial growth
diovascular Surgery c Volume 144, Number 6 1491
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FIGURE 4. Picosirius red and trichrome staining for collagen and intramyocardial fibrosis showing no difference in collagen area fraction or fraction of
intramyocardial fibrosis in oral hypercaloric/hypercholesterolemic diet plus 1.5 mg/kg atorvastatin daily (OHCS) compared with oral hypercaloric/hyper-
cholesterolemic diet (OHC) groups.
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loop in which VEGFR2 activation leads to receptor
internalization.20
The significant increase in angiogenesis in a swine
model of the metabolic syndrome supplemented with
low-dose atorvastatin is in contrast to a previous study con-
ducted in our laboratory in which we showed a decreased
angiogenic response to high-dose atorvastatin.6,7 These
results confirm previous animal and cell culture studies
demonstrating that statins have a biphasic, dose-
dependent effect on angiogenesis.4,5 At high statin doses,
toxic mevalonate-derived intermediates are increased as
a result of statin-mediated inhibition of biosynthetic path-
ways that rely on mevalonic acid as a precursor. The meval-
onate intermediates lead to endothelial progenitor cell
apoptosis and angiostasis.5 At lower statin doses, endothe-
lial progenitor cell survival is preserved and angiogenesis
promoted.4
An interesting result was the significant increase in
myocardial protein oxidation and serum lipid peroxida-
tion. These results were similar to our previous study
of high-dose atorvastatin treatment.21 Statins have been
reported to have systemic antioxidant properties based
on an assessment of oxidative stress markers in blood
and urine.22,23 No difference was seen in the expression
of proteins involved in oxidative stress, such as NOX2,
RAC1, myeloperoxidase, SOD1, SOD2, or SOD3. Thus,
the mechanism for the increased oxidative stress has
yet to be elucidated. Perhaps the increased tissue and
peripheral oxidative stress results from statin-mediated
inhibition of the reducing agent Q10, resulting in redox
imbalance toward oxidation.24 The clinical significance
of the increased oxidative stress is unclear; however, it
is possible that the oxidative stress contributed to
the increased angiogenic response in the ischemic
myocardium.25
Although angiogenesis was significantly increased, this
did not result in the expected increase in myocardial1492 The Journal of Thoracic and Cardiovascular Surperfusion. Three reasons could explain this result. First,
atorvastatin increased oxidative stress in the serum and is-
chemic myocardium, as previously reported.21 Increased
oxidative stress, in turn, could result in vasoconstriction ow-
ing to a reduction of bioavailable nitric oxide. This could
account for the lack of improved perfusion.26 In contrast
to previous studies, the microvessel reactivity was not dif-
ferent between the 2 groups. With increased oxidative
stress, one would predict a reduction in endothelium-
dependent relaxation as a result of diminished bioavailable
nitric oxide. This could be due to the in vitro examination of
the microvessels, in which they are removed from the oxi-
dative environment before the vascular experiments. Sec-
ond, quantification of CD31-positive endothelial cells
identifies all vessels, including the immature, leaky, unsta-
ble capillaries that might not contribute to myocardial per-
fusion. Third, myocardial perfusion is more reflective of the
larger arteriole vessel blood supply and not dependent on
capillary-mediated perfusion.
Study Limitations
Although providing important functional and molecular
data on the role of low-dose atrovastatin in chronic myocar-
dial ischemia, the present study had several limitations.
First, although atorvastatin is 1 of the most commonly pre-
scribed statins, these results are not necessarily generaliz-
able to all statins currently prescribed. For example,
cerivastatin has been shown to have overall angiostatic ef-
fects by inhibiting endothelial cell migration and increased
cell cycle arrest.27 Second, because all cardiac tissue was
harvested at a single point, 11 weeks after ameroid constric-
tor placement, it is likely that some of the acute and longer
term changes in angiogenesis and vessel maturation were
not captured in this model. Third, morphometric analysis
of new vessel formation by quantification of CD31-
positive endothelial cells identifies all vessels, including
the newly formed, immature, unstable capillaries that might
not contribute to myocardial perfusion. This could alsogery c December 2012
Elmadhun et al Evolving Technology/Basic Scienceaccount for the increased angiogenesis, without the
expected increase in perfusion.
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